Psychotropic Medications Use among Children with Autism in Saudi Arabia
- PMID: 35883950
- PMCID: PMC9322379
- DOI: 10.3390/children9070966
Psychotropic Medications Use among Children with Autism in Saudi Arabia
Abstract
Psychotropic medication use is rising among children with autism spectrum disorders (ASD) in Saudi Arabia. Two hundred ninety-three parents of children diagnosed with ASD completed a parental concerns questionnaire (PCQ) online to examine children’s family socio-demographics, health conditions and comorbidities, and past and current exposure to psychotropic medication as prescribed by their primary doctor. Findings revealed that more than one-third of the parents (39.08%) reported that their children were using medications at the time of the survey; risperidone (53%), methylphenidate (30%), and valproic acid (9%) were the most commonly used. A smaller number of parents stated that their children had previously used medications (16.09%). The most often prescribed drugs among this group were risperidone (45%), followed by methylphenidate (32%) and valproic acid (17%). The variables that showed a statistically significant association with the current use of psychotropic drugs were the child’s age (OR = 1.25, 95% CI: 1.12, 1.40, p < 0.001), presence of comorbidities (OR = 7.75, 95% CI: 3.48, 17.24, p < 0.001), communication difficulties (OR = 1.79, 95% CI: 1.09, 2.95, p < 0.021), and anxiety symptoms (OR = 1.70, 95% CI: 1.00, 2.87, p < 0.049). Similarly, the child’s age (OR = 1.23, 95% CI: 1.08, 1.40, p < 0.002) and presence of comorbidities (OR = 2.83, 95% CI: 1.16, 6.29, p < 0.022) showed statistically significant associations with previous use.
Keywords: Saudi Arabia; autism spectrum disorder; psychotropic medications.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Psychiatric Comorbidities and Psychotropic Medication Use in Autism: A Matched Cohort Study with ADHD and General Population Comparator Groups in the United Kingdom.Autism Res. 2018 Dec;11(12):1690-1700. doi: 10.1002/aur.2040. Epub 2018 Oct 31. Autism Res. 2018. PMID: 30380202
-
Stress and emotional wellbeing of parents due to change in routine for children with Autism Spectrum Disorder (ASD) at home during COVID-19 pandemic in Saudi Arabia.Res Dev Disabil. 2021 Jan;108:103822. doi: 10.1016/j.ridd.2020.103822. Epub 2020 Nov 30. Res Dev Disabil. 2021. PMID: 33271447
-
Attitude, anxiety and perceived mental health care needs among parents of children with Autism Spectrum Disorder (ASD) in Saudi Arabia during COVID-19 pandemic.Res Dev Disabil. 2021 Apr;111:103873. doi: 10.1016/j.ridd.2021.103873. Epub 2021 Feb 2. Res Dev Disabil. 2021. PMID: 33540358
-
Pharmacological management of behavioral disturbances in children and adolescents with autism spectrum disorders.Curr Probl Pediatr Adolesc Health Care. 2018 Oct;48(10):250-264. doi: 10.1016/j.cppeds.2018.08.015. Epub 2018 Sep 24. Curr Probl Pediatr Adolesc Health Care. 2018. PMID: 30262163 Review.
-
Dental experiences related to oral care of children with autism spectrum disorders in Saudi Arabia: A literature review.Saudi Dent J. 2022 Jan;34(1):1-10. doi: 10.1016/j.sdentj.2021.09.023. Epub 2021 Sep 27. Saudi Dent J. 2022. PMID: 35068893 Free PMC article. Review.
Cited by
-
Findings of a Multidisciplinary Assessment of Children Referred for Possible Neurodevelopmental Disorders: Insights from a Retrospective Chart Review Study.Behav Sci (Basel). 2022 Dec 14;12(12):509. doi: 10.3390/bs12120509. Behav Sci (Basel). 2022. PMID: 36546992 Free PMC article.
References
-
- Aman M.G., Mcdougle C.J., Scahill L., Handen B., Arnold L.E., Johnson C., Stigler K.A., Bearss K., Butter E., Swiezy N.B., et al. Medication and Parent Training in Children With Pervasive Developmental Disorders and Serious Behavior Problems: Results From a Randomized Clinical Trial. J. Am. Acad. Child Adolesc. Psychiatry. 2009;48:1143–1154. doi: 10.1097/CHI.0b013e3181bfd669. - DOI - PMC - PubMed
-
- Marcus R.N., Owen R., Manos G., Mankoski R., Kamen L., McQuade R.D., Carson W.H., Corey-Lisle P.K., Aman M.G. Aripiprazole in the Treatment of Irritability in Pediatric Patients (Aged 6–17 Years) with Autistic Disorder: Results from a 52-Week, Open-Label Study. J. Child Adolesc. Psychopharmacol. 2011;21:229–236. doi: 10.1089/cap.2009.0121. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous